Good MorningEquities moved higher on Wednesday despite a hot reading of the CPI. The CPI came in at 0.5% for the month or up a tenth hotter than expected with similar strength at the core and YOY levels. The takeaway is that inflation continues to rise and is leaving the FOMC no choice but to raise rates. Based on Jerome Powell’s testimony to Congress it looks like the Fed will be raising rates at a much quicker pace than ever indicated. According to the CME’s FedWath Tool, a rate hike is all but assured at the March FOMC meeting.
Today’s action will be driven by the PPI. The Producer Price Index is expected to subside from the previous month but could easily come in hotter than expected. Even so, with CPI already at record levels, a cool read on the PPI will do little to alter the outlook. The question is how will the market react?
Featured: 100% overnight gains? (Ad) 
|
Consumer Staples | |
Energy drink maker Monster Beverage (NASDAQ: MNST) shares have been rallying despite the market sell-off on merger speculation. The rising costs of aluminum, shipping costs and supply chain disruptions hurt margins resulting in a miss on in its Q3 2021 earnings report. While the Company doesn&rsqu... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Technology | |
Consider Adding These 3 Stocks Trading Under $100
One of the most attractive qualities of the stock market is that you don’t necessarily have to be a big spender in order to capitalize on the potential for long-term gains. Quality companies are priced at all different levels, and investors ... Read the Full Story |
|
Markets | |
There's no secret that real estate was a dizzying rollercoaster in 2021. If you didn't dip into real estate investing last year, here's a quick summary of what happened:
The pandemic completely bent the home-buying process last year. Low mortgage interest rates combined with an inventory shortag... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Markets | |
Since 2011, MarketBeat has made it our mission to give individual investors a way to level the playing field with institutional investors. We noticed there was a lack of high-quality stock research tools for investors of all levels. And even if there was, there was no place for investors to go as ... Read the Full Story |
|
Consumer Discretionary | |
The Rebound In Lululemon Athletica Is On
After falling more than 31% from the all-time high set in late 2021 shares of Lululemon Athletica (NASDAQ: LULU) are ready to rebound. The market caved in the wake of the updated Q4 guidance and may move lower but we don’t think so. The market caved ... Read the Full Story |
|
From Our Partners | | AI is expanding beyond software into robots, factories, vehicles, and intelligent machines. That shift could create a new group of market leaders before most investors notice.
A complimentary report, 5 Stocks Powering the Physical AI Revolution, identifies five companies positioned at the center of this shift, along with the technologies, growth drivers, and risks to understand. | | Get your free copy before physical AI becomes Wall Street's next crowded trade |
|
Consumer Staples | |
Albertsons Slips After Strong Earnings, Upward Guidance
Albertsons Companies (NYSE: ACI) has been working hard on improving its business over the past year or two and those efforts are showing up in the results. The company reported better than expected earnings for FQ3 and gave favorable guidanc... Read the Full Story |
|
Markets | |
Accolade, Inc Is Poised For A Major Rebound
Accolade, Inc (NASDAQ: ACCD) caught our attention last year after it IPOd. The company is a business-services provider that offers a cloud-based platform that helps employees understand and utilize their healthcare benefits. The company’s revenue... Read the Full Story |
|
Communication Services | |
The glory days appear to be over for Roku (NASDAQ: ROKU) shareholders. After the digital media device maker’s stock price twice climb to nearly $500, it’s been a horror show on the way down. Last week Roku fell to a fresh 52-week low and more than 60% from its July 2021 peak.
While so... Read the Full Story |
|
Markets | |
Adaptive network solutions provider Ciena Corporation (NYSE: CIEN) stock exploded higher on its fiscal Q4 2021 earnings release hitting multi-year highs. The optical fiber leader is benefitting from the 5G buildout and digital transformation among the 30 largest global carriers. The Company is exp... Read the Full Story |
|
Healthcare | |
OrganiGram Gave The Market What It Wanted
We were only interested in one thing, really, when it came to OrganiGram’s (NASDAQ: OGI) FQ1 performance and that was profitability. We weren’t expecting the company to turn a profit but we wanted news on when it might be profitable because t... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. | | View Today's Stock Pick |
|
